Bifogade filer
Kurs
+0,98%
Likviditet
0,37 MSEK
Kalender
Est. tid* | ||
2025-08-22 | 10:00 | Bokslutskommuniké 2025 |
2025-05-15 | - | Extra Bolagsstämma 2025 |
2025-05-09 | - | Kvartalsrapport 2025-Q3 |
2025-02-07 | - | Kvartalsrapport 2025-Q2 |
2024-11-04 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2024-11-01 | - | Årsstämma |
2024-10-28 | - | Kvartalsrapport 2025-Q1 |
2024-08-30 | - | Bokslutskommuniké 2024 |
2024-04-19 | - | Kvartalsrapport 2024-Q3 |
2024-04-12 | - | Extra Bolagsstämma 2024 |
2024-02-09 | - | Kvartalsrapport 2024-Q2 |
2023-10-27 | - | Kvartalsrapport 2024-Q1 |
2023-09-25 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2023-09-22 | - | Årsstämma |
2023-08-31 | - | Bokslutskommuniké 2023 |
2023-05-04 | - | Kvartalsrapport 2023-Q3 |
2023-02-09 | - | Kvartalsrapport 2023-Q2 |
2022-10-27 | - | Kvartalsrapport 2023-Q1 |
2022-10-07 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2022-10-06 | - | Årsstämma |
2022-08-30 | - | Bokslutskommuniké 2022 |
2022-07-05 | - | Extra Bolagsstämma 2022 |
2022-05-04 | - | Kvartalsrapport 2022-Q3 |
2022-02-11 | - | Kvartalsrapport 2022-Q2 |
2021-10-22 | - | Kvartalsrapport 2022-Q1 |
2021-10-06 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2021-10-05 | - | Årsstämma |
2021-08-30 | - | Bokslutskommuniké 2021 |
2021-05-12 | - | Kvartalsrapport 2021-Q3 |
2021-02-12 | - | Kvartalsrapport 2021-Q2 |
2020-11-12 | - | Kvartalsrapport 2021-Q1 |
2020-10-08 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2020-10-07 | - | Årsstämma |
2020-08-31 | - | Bokslutskommuniké 2020 |
2020-05-15 | - | Kvartalsrapport 2020-Q3 |
2020-05-04 | - | Extra Bolagsstämma 2020 |
2020-02-14 | - | Kvartalsrapport 2020-Q2 |
2019-11-01 | - | Kvartalsrapport 2020-Q1 |
2019-10-10 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2019-10-09 | - | Årsstämma |
2019-08-30 | - | Bokslutskommuniké 2019 |
2019-05-16 | - | Kvartalsrapport 2019-Q3 |
2019-02-14 | - | Kvartalsrapport 2019-Q2 |
2018-10-30 | - | Kvartalsrapport 2019-Q1 |
2018-10-17 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2018-10-16 | - | Årsstämma |
2018-08-31 | - | Bokslutskommuniké 2018 |
2018-05-16 | - | Kvartalsrapport 2018-Q3 |
2018-02-14 | - | Kvartalsrapport 2018-Q2 |
2017-10-30 | - | Kvartalsrapport 2018-Q1 |
2017-10-02 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2017-09-29 | - | Årsstämma |
2017-08-30 | - | Bokslutskommuniké 2017 |
2017-05-22 | - | Kvartalsrapport 2017-Q3 |
2017-02-20 | - | Kvartalsrapport 2017-Q2 |
2017-01-25 | - | Extra Bolagsstämma 2017 |
2016-11-07 | - | Kvartalsrapport 2017-Q1 |
2016-08-29 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2016-08-26 | - | Bokslutskommuniké 2016 |
2016-05-26 | - | Kvartalsrapport 2016-Q3 |
2016-02-25 | - | Kvartalsrapport 2016-Q2 |
2015-11-26 | - | Kvartalsrapport 2016-Q1 |
2015-08-27 | - | Bokslutskommuniké 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
VibroSense Dynamics AB (VibroSense) has received an "Intention to grant" from the Swedish Patent Office and a positive Written Opinion from an international PCT application. The patent covers an important part of VibroSense's measurement technology to measure skin temperature continuously during an examination with VibroSense Meter® II.
- We are continuously working to strengthen the company's IP protection and with our latest patent we have now extended the protection until 2040. Our long-term IP protection strategy is based on our continuous efforts to seek new patents as we obtain clinical data that we deem patentable," says Hans Wallin, CEO of VibroSense Dynamics AB.
Contact VibroSense Dynamics AB
Hans Wallin, CEO VibroSense Dynamics AB,
Phone: +46 40 88 026
E-mail: info@vibrosense.com
www.vibrosense.com
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) manufactures and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.